In a genome-wide linkage survey, we have previously shown evidence suggesting that the chromosome 22q12 region contains a susceptibility locus for bipolar disorder (BPD). Two independent family sets yielded lod scores suggestive of linkage at markers in this region near the gene G protein receptor kinase 3 (GRK3). GRK3 is an excellent candidate risk gene for BPD since GRK3 is expressed widely in the brain, and since GRKs play key roles in the homologous desensitization of G protein-coupled receptor signaling. We have also previously shown GRK3 expression to be induced by amphetamine in an animal model of mania using microarraybased expression profiling. To identify possible functional mutations in GRK3, we sequenced the putative promoter region, all 21 exons, and intronic sequence flanking each exon, in 14-22 individuals with BPD. We found six sequence variants in the 5 0 -UTR/promoter region, but no coding or obvious splice variants. Transmission disequilibrium analyses of one set of 153 families indicated that two of the 5 0 -UTR/promoter variants are associated with BPD in families of northern European Caucasian ancestry. A supportive trend towards association to one of these two variants (P-5) was then subsequently obtained in an independent sample of 237 families. In the combined sample, the P-5 variant had an estimated allele frequency of 3% in bipolar subjects, and displayed a transmission to non-transmission ratio of 26 : 7.7 (v 2 ¼ 9.6, one-sided P value ¼ 0.0019). Altogether, these data support the hypothesis that a dysregulation in GRK3 expression alters signaling desensitization, and thereby predisposes to the development of BPD.
Bipolar disorder (BPD) is a severe psychiatric disorder that affects approximately 1% of the world's population. A variety of family epidemiological data have long argued for a strong genetic component. Twin studies have generally reported a concordance rate in monozygotic twins of approximately 60% compared to a rate in dizygotic twins of 15%. 1 Firstdegree relatives of probands have a 7% risk for BPD, and a two-fold increase in risk for unipolar disorder. [2] [3] [4] While the mode of inheritance remains unclear, segregation analyses of family data have generally suggested a complex mode of inheritance, although several recent large samples have reported evidence for autosomal dominant major gene effects. 3, 5 More than 10 genome-wide linkage scans have been published, and many additional scans which are in progress have reported some findings for selected chromosomal regions. 6 A number of chromosomal loci have now been reported in multiple studies including: 4p, 5q, 10q, 12q, 13q, 16p, 18p, 18q, 21q, 22q. Some of these regions have met the proposed rigorous criteria for statistical significance and replication. 6, 7 A meta-analysis of 11 whole-genome linkage scans found the strongest evidence for susceptibility loci for BPD on 13q and 22q. 8 We first reported evidence for linkage to the proximal portion of 22q in a study of 13 families. 9 A maximum lod score of 2.5 was obtained at D22S303 (position (pos.) 20.1 Mb per NCBI). We subsequently expanded this set to 20 families and reported a genome-wide maximum lod score of 3.8 at D22S278 (pos. 33.2 Mb) at 22q13. 10 However, lod scores !1.0 spanned a region of 32 cM (according to the Marshfield sex-averaged map) covering most of 22q, and appeared to include possibly two distinct regions for which there was suggestive evidence of linkage. The second putative peak in lod scores was located more proximally at 22q12.1, where a maximum lod score of 2.2 was obtained at D22S419 (pos. 22.7 Mb). The genetic and physical distances between these markers are consistent with a reported increased rate in recombination on 22q such that the 10.5 Mb between D22S419 and D22S278 is equivalent to 15 cM (Sanger Centre web site, Marshfield Map). In a recent followup study of a second independent set of 32 families (to be reported separately), we obtained the maximum evidence for linkage on chromosome 22 at precisely this same 22q12.1 locus. The combined analysis of these 52 families produced a peak NPL score for chromosome 22 of 2.45 at D22S925 (pos. 22.5 Mb) with an apparent 1-lod support interval centered at this marker and spanning 8-10 cM.
Support for this region also comes from the NIMH Genetics Initiative for Bipolar Disorder consortium. 11 In a study of 97 families, they reported a peak lod score for chromosome 22 of 2.5 at the marker D22S533 (pos. 22.6 Mb) . Under the disease model that gave the maximum score at D22S533, lod scores of 0.3 and 0.7 were obtained at flanking markers B8 cM centromeric and B7 cM telomeric to D22S533. These studies on three independent family sets (and a total of 149 families) thus support a distinct peak in evidence for linkage in the 22q12.1 region.
An attractive candidate gene in this region is G protein receptor kinase 3 (GRK3) located just 40 kb telomeric to the marker D22S419. In the continuing presence of high agonist concentrations, signaling of a G protein-coupled receptor (GPCR) is rapidly terminated via a process termed homologous desensitization. During the initial phase of homologous desensitization, a G protein receptor kinase (GRK) phosphorylates serines and/or threonines in the activated GPCR's C-terminus or in the third intracellular loop. [12] [13] [14] [15] [16] There are only seven known members of the GRK family of genes, but hundreds of neurotransmitter GPCRs. GRK3 is widely expressed in the brain including regions of the limbic system 17, 18 and has been demonstrated to phosphorylate multiple GPCRs critical for brain neurotransmission including adrenergic, muscarinic, histaminic, dopamine, and corticotropin-releasing factor (CRF) receptors. [12] [13] [14] [15] [16] [19] [20] [21] Support for the role of the GRK3 gene also comes from a recent animal model study we have conducted. 22 The behavioral hyperactivity induced by amphetamines in animals and man mimics aspects of mania, and hence has been suggested to model components of the pathophysiology of mania. Using an oligonucleotide-based microarray expression profiling method, we found, in rats, a 14-fold increase in GRK3 mRNA in the prefrontal cortex 24 h following administration of methamphetamine. In fact, GRK3 displayed the largest change in the expression of any of the 8000 genes examined in the prefrontal cortex. These data argue that GRK3 plays a substantial role in the brain's homeostatic response to dopamine and possibly other neurotransmitters.
The biological function, anatomical distribution, and chromosomal location of GRK3 led us to prioritize it as a positional candidate in this region of 22q. For these reasons, we have conducted a detailed examination of GRK3 in bipolar subjects in search of potential pathogenic mutations, and have examined several resulting single nucleotide polymorphisms (SNPs) for association to BPD.
Methods

Subjects
Two independent sets of families were analyzed. Probands were first drawn from set 1 described below for mutation screening. Parent-proband triads from set 1 were then used for association analysis. Subsequently, set 2 was examined for association.
Set 1: UCSD and NIMH triads A total of 153 nuclear families with 227 affected children were drawn from the UCSD and NIMH BP pedigrees. Of these families, 47 families were ascertained from the general North American population as part of the UCSD collaborative linkage study. 10 These families were collected at UCSD and at two collaborating sites, the University of British Columbia and the University of Cincinnati. Families were ascertained through a proband with either bipolar I (BP I) or bipolar II disorder (BP II), and were required to have a minimum of two additional members affected with either bipolar disorder or recurrent major depression. These families were derived from two independent linkage sets. The first (UCSD 20) included 20 families and 164 members and was used for our recently reported genome scan. 10 The second set (UCSD 32) includes 32 families now being studied as a replication set.
Informed consent procedures approved by each institution's institutional review board were employed. After informed consent was obtained, each family member was directly interviewed using the Structured Clinical Interview for DSM-III-R (SCID; in the case of the first set of 20 families) or the SCID for DSM-IV (in the case of the second set of families). As described previously, 10 information from the interview, other family members and medical records were reviewed by a panel of experienced clinicians in order to determine a consensus, best-estimate diagnosis. Blood was obtained from each subject for the establishment of lymphoblastoid cell lines and preparation of DNA.
DNA was obtained for an additional 106 families from the NIMH Genetics Initiative for Bipolar Disorder first wave pedigree collection. 11 This sample was collected as part of a four-site collaboration whose ascertainment and diagnostic procedures have been described previously.
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Association of GRK3 with bipolar disorder TB Barrett et al A total of 153 families were drawn from these three pedigree collections. In all families, the affected offspring were diagnosed with either BP I or BP II. Families were considered to be of a single ancestral ethnic/geographic origin if three or more grandparents were reported to be of similar ancestral origin. On this basis, 130 families were classified as northern European Caucasian. For 23 families, two or more grandparents were reported to have been of Ashkenazi Jewish, Mediterranean, Hispanic, African-American, Asian, or native American origin. Of the 130 northern European Caucasian families, 64 consisted of parent-offspring triads, 65 consisted of parents plus two affected siblings, and one consisted of parents plus three affected siblings. Altogether thereby, a total of 197 triads were extracted from the 130 Caucasian pedigrees.
Set 2: University of Toronto triads A total of 275 triads ascertained through probands with BP I or BP II disorders from Toronto and across Central Canada 23 were analyzed. Subjects were interviewed using SCID-I 24 and diagnoses were made using DSM-IV criteria by a 'best estimate' procedure. In all, 237 families, with 242 affected offsping, were Caucasian of northern European ancestry, mostly from Great Britain, 33 families were Caucasian of southern European or Mediterranean ancestry, mostly Italian and Jewish, and five families were not Caucasian.
Sequencing, mutation screening and sequence analysis To enrich the sample for subjects likely to contain a functional mutation in the GRK3 gene, families showing the most strongly positive lod scores for the markers D22S419 and D22S315 were selected from the UCSD family set and the 57-family NIMH subset which we previously used for a reanalysis of chromosome 22.
10 From the 12 families with the highest lod scores, 14 bipolar subjects were selected and sequenced over all the regions described below. An additional eight subjects from six families were sequenced just in the promoter region.
To identify variants, we sequenced the promoter region, exons, flanking intronic region, and 5 0 -UTR in subjects with BPD. The GRK3 gene spans 170 kb and has 21 exons ranging in size from 52 to 163 bp. Using genomic sequence from the Sanger Centre, we designed PCR primers to amplify B500 bp genomic DNA fragments centered on each of the 21 exons and including approximately 200 bp of flanking intronic sequence (see Table 1 for positions of amplified fragments). (Primers and reaction conditions are available at http://psychgenes.ucsd.edu.) Primers were also designed to amplify 1.5 kb in the 5 0 promoter region immediately upstream of exon 1 and 1.5 kb of the 3 0 -UTR immediately downstream of the coding portion of exon 21, each in overlapping segments. Fragments were sequenced bidirectionally using the Perkin Elmer Big Dye fluor-ddNTP sequencing kit and an ABI 377 sequencer, according to the manufacturer's recommendations. Minor modifications were used for sequencing the GC-rich region of the promoter (annealing temperature of 541C and addition of 5% DMSO). Using these methods, we obtained full bidirectional sequence for all fragments examined except for a 38-bp region located 3 0 to P-6 (ntds.1497-1534 in Figure 2 ). Sequencing gels were tracked and data extracted using ABI sequence analysis software. Chromatogram files were then transferred to a Sun Unix workstation for assembly into contigs using the Pred/Phrap/Consed suite of programs and SNPs were identified using Polyphred 25 and by visual inspection. All promoter and exon sequence was visually scanned to evaluate sequence quality, confirm SNPs, and check for possible false negatives (missed SNPs). Likewise, any regions of reduced sequence quality (o30 on the Pred/Phrap scale, or approx. error rate of 1 : 1000) were visually inspected and resequenced if necessary. All regions where sequence was visually inspected showed no discrepancy with Polyphred calls. To compare human to mouse promoter sequence, murine genomic sequence which terminated 227 bp 5 0 to exon 1 was downloaded from the Celera Discovery System (4GA_x5J8B7W5ADD, http://www.celera.-com) and spliced to a murine sequence from the NCBI database (mmtrace sequence 4gnl|ti|19424054 G10P638823RD9.T0) extending from 481 bp 5 0 of exon 1 through exon 1. Human GRK3 sequence was downloaded from the Sanger Centre web site. Alignment of the human and mouse putative promoter regions was performed using NCBI's ''Blast 2 Sequences'' with the settings: match 2, mismatch À1, gap open 6, gap extension 0.4, Â _dropoff 50, expect 10.0, word size 7.
Genotyping
Single base substitution SNPs selected for analysis were genotyped by the TaqMan allele specific assay method (Applied Biosystems) according to the manufacturer's protocols. For each site, primer pairs flanking the site to be interrogated were selected for PCR amplification of fragments of o150 bp (primers, probes, and reaction conditions are available at http:// psychgenes.ucsd.edu). Two dual labeled probes centered on the SNP and differing in sequence by the 1-bp polymorphism of the SNP site itself were designed. The probes were labeled with 5 0 reporter fluors FAM or TET and 3 0 quencher TAMARA. Sensitivity and specificity for allelic discrimination were tested over a wide range of primer and probe concentrations on the DNA samples whose allele type was known by sequencing. Concentrations and cycling parameters were chosen for genotyping that produced clustered values for heterozygotes which separated from homozygotes by 44 standard deviations. Samples which gave ambiguous calls were retyped. Accuracy of typing was checked by retyping all 7 SNPs on 180 samples of triad set 1 and the SNP P-5 on 450 samples of triad set 2. No incorrect calls were detected.
We could not develop TaqMan reagents for a 5 0 -UTR single base deletion variant (P-6). Instead we typed it by standard size-based methods used for microsatellite genotyping. An FAM-labeled forward and unlabeled reverse primer pair were used to amplify a 228-bp genomic fragment spanning the variant. (Primers: fwd FAM-cgaccccggccggctacag, rev tcggccagcacagcctccag. Reaction mix: FailSafe PCR Enzyme Mix (Epicentre Technologies, Madison, WI, USA), buffer G, 0.25 mM primers, 40 ng genomic DNA in a 25 ml reaction. Thermal cycling: 821C for 10 min, 981C for 3 min, then four cycles of 981C for 60 s, 711C for 30 s less 0.51C per cycle, 721C for 45 s, followed by 38 cycles of 981C for 60 s, 671C for 45 s, 721C for 30 s.) The 1-bp deletion was detected by size discrimination on a sequencing gel. All genotypes were read in a machine-assisted fashion using ABI software and confirmed by two independent human readers.
Transmission disequilibrium test (TDT) analysis
TDTs were carried out using the program Transmit. 26 Transmitted and non-transmitted alleles are counted from each heterozygotic parent to affected offspring. For triads in which a parental genotype is missing, alleles or haplotypes are estimated. Additional offspring can be included in the analysis without the association statistic being inflated by the presence of linkage by using the 'robust' empirical estimate of variance. 26 
Results
Identification of sequence variants
We sequenced 1500 bp of the putative promoter region, all 21 exons and approximately 200 bp of flanking intronic region, plus 1500 bp of the 3 0 -UTR in 14 bipolar subjects. We also sequenced the promoter region in an additional eight bipolar subjects. No SNPs were identified in the coding region. Seven SNPs were identified in intronic regions flanking exons ( Figure 1 and Table 2 ), but none of these is anticipated to affect splicing nor generate a new splice site. Only one of these intronic SNPs (A630) was a 'high frequency' SNP, found by genotyping to have an allele frequency of 36% in triad set 1. Each of the six other intronic SNPs was observed in only a single chromosome. Four were found in one subject and two in another subject. Because of their low frequency, we did not genotype these SNPs.
The GRK3 promoter has yet to be functionally identified. However, based on the following three points, we reasoned that the promoter for GRK3 lies in the genomic region immediately 5 0 to the first coding exon 1. (1) The region is GC rich (75% GC over a 500-bp region just upstream of exon 1 with a maximum of 94% GC for 104 bp). (2) The region meets the definition for a CpG island (http:// www.sanger.ac.uk). 3. The analogous 5' region of the GRK2 gene has been demonstrated to have promoter activity by expression vector assays and has been shown by RNA protection assays to contain the transcription start site. 27 We identified 6 SNPs within the 1500-bp putative GRK3 promoter region (Table 2 and Figure 2 ). Four of these SNPs, P-1, -2, -5, and -6, were observed on more than one chromosome and were selected for genotyping.
In addition, as part of an independent ongoing project to examine linkage disequilibrium (LD) across a broader region in the vicinity of GRK3 (which will be reported elsewhere), we identified a second highfrequency SNP in the 3 0 region of GRK3 plus 2 highfrequency SNPs 28 kb upstream of GRK3 by direct sequencing of genomic DNA. The 3 0 SNP has also been identified by Celera (Celera Discovery System) and the two 5 0 high-frequency SNPs have also been identified in the NCBI dbSNP database (http:// www.ncbi.nlm.nih.gov)). We genotyped these four high-frequency flanking SNPs and the four promoter SNPs in set 1 of the bipolar triads. Two of the promoter SNPs were subsequently genotyped in triad set 2.
Alignment of the human and mouse GRK3 promoter regions To determine if the variants in the putative promoter region affect evolutionarily conserved regulatory motifs, we compared the human to mouse sequence 5 0 to and including exon 1 (see Figure 3 ). Exon 1 is highly conserved: 92% identity over 113 bp. A stretch of 35 bp located at human -1640 bp (with respect to the ATG of exon 1) and at mouse -1078 is 86% identical. Over the intervening sequence, stretches of moderate alignment are evenly distributed: there are seven short blocks, from 9 to 12 bp long, of complete identity and B500 bp total of !70% identity. A GArich region lies 5 0 to P-5 (67 bp with 96% GA in human and 73 bp with 100% GA in mouse). A GCrich region lies 3' to P-5 and extends to exon 1 (251 bp with 89% GC in human and 119 bp with 87% GC in mouse). Of note, all six SNPs in the putative promoter region fall in sequence of low to no identity. Only for P-2 is the variant base conserved between human and mouse. Both P-5 and P-6 lie in regions of no human to mouse homology. P-6 is a single G deletion at the base of a 28-nucleotide potential hairpin structure that comprised 12 aligning G-C pairs.
Searches run on the web site Transcription Element Search System (TESS, http://www.cbil.upenn.edu) 28 Table 3 shows results for triad set 1 of transmission disequilibrium analyses done using Transmit on genotype data for the four promoter SNPs selected for testing. The number of times a marker was transmitted or not transmitted from a heterozygous parent to an affected child is shown. For P-1 there were 20 transmissions and six non-transmissions observed, and for P-5 there were 15 transmissions and four non-transmissions observed. Transmitted and non-transmitted alleles are counted from each heterozygotic parent to affected offspring. Fractional values are contributed by a small number of triads for which one parental genotype was missing. w 2 statistics were derived using the 'robust' option for estimation of variance, which uses an empirically derived variance-covariance matrix that corrects for the presence of more than one affected offspring in some triads. 26 Promoter SNPs were tested under the a priori hypothesis that the rare variant is a risk allele and will be associated with an excess of transmissions. Therefore, the significance of w 2 is assessed by one-sided P values. Two SNPs had P values less than 0.05. For P-1 w 2 ¼ 5.6, P value ¼ 0.018, and for P-5 w 2 ¼ 6.0, P value ¼ 0.014. Empirical P values computed using 100,000 replications were similar to those derived from the 'robust' w 2 statistic; however, Transmit failed to produce P values for some of the data points, and therefore only the 'robust' values are listed in the tables. These P values are not corrected for multiple testing. Also, because of the strong LD among markers, these tests are not fully independent.
TDT analysis
Haplotypes could be unambiguously assigned for all triads except one. Only six haplotypes for these four SNPs were observed (see Table 3 ), indicating a high degree of LD among the markers as anticipated by their close proximity. As they are all in tight LD, it is not possible to determine from these triads which of the three SNPs, P-1, P-5, or P-6, is most likely to be functionally relevant, or to exclude the possibility that the functional SNP is some other nearby variant not yet identified.
In order to attempt to define the extent of the region of association, we also genotyped four additional SNPs. One of these was an intronic SNP 3 0 of exon 9 (A630) identified as part of the studies described above. Another SNP in intron 18 (A665) and two others, approximately 28 kb upstream of exon 1 (A486a and A486b); were identified as part of a study of LD across a larger genomic region and will be reported separately. The analyses of these four flanking SNPs, located 28 kb upstream and 114 and 150 kb downstream, considered individually and as bi-allelic haplotypes, were uniformly negative (Table 4 ). This provides some evidence to restrict the region of association to the approximately 140 kb containing the 5 0 end of the gene. These data observed for the promoter region SNPs in the first triad set suggest a significant association with susceptibility for disease. To verify this we genotyped two of these SNPs in a second independent set of triads recruited at the University of Toronto from eastern Canada. Notably, these data (Table 5) show a strong trend toward association for P-5 among northern European Caucasians. For P-1 all excess transmissions were accounted for by the P-1/5 haplotypes. w 2 analysis of the combined data set is shown in Table 6 . For P-5 a total of 26 transmissions and 7.7 non-transmissions were observed when the two sets were combined for a w 2 of 9.6 and an associated P value of 0.0019. A global test incorporating all three observed haplotypes was also significant (w 2 ¼ 10.0, P ¼ 0.019). Although the number of Caucasian triads not of northern European origin is small and the number of non-Caucasian triads is also small, the data suggest that there is no trend toward excess transmission of any of the promoter markers in either of these groups.
To examine haplotype structure across this region, we determined LD among all pairs of SNPs. As anticipated by their physical proximity, the two 5 Association of P-5 with the evidence for linkage at 22q12.1 If the variant P-5 is indeed associated with disease, we would then expect that P-5 would be present in those families contributing to the linkage evidence that we observed at D22S419, the microsatellite immediately centromeric to GRK3. Of the 153 families from which triads were drawn for triad set 1, 73 have been analyzed for linkage as part of the three data sets (UCSD 20, UCSD 32, and NIMH) described above. We examined the lod scores for subsets of these 73 families. Only seven of these families had the P-5 variant. Therefore, because of this limited amount of data, it is not possible to make definitive conclusions about the portion of linkage evidence at D22S419 that is explained by P-5. One of the two families with P-5 from the UCSD 20 set yielded a lod score of 0.91. This compares to a summed lod score of 0.71 in the P-5 negative families in this family set. This suggests that P-5 makes a disproportionate contribution to the total lod score at this locus in this family set. The entire UCSD 32 family set provides additional support for linkage to the GRK3 region (to be reported separately). However, little evidence for linkage at D22S419 is present in either the one family with P-5 or the 14 without. Therefore, this family set contributes little information to this question. Similarly, in the NIMH set, three families with P-5 contribute little to the total lod score of 1.49 observed in the 38 northern European Caucasian families. In addition, two native American families, one with P-5 and one without, had individual family lods of 0.60 and 0.11. Hence, while families with haplotypes marked by the variant P-5 contributed to the total linkage among the subset of families of northern European Caucasian ancestry, families with other haplotypes (haplotypes without P-5) contributed more overall to the evidence for linkage at 22q12.1 among these northern European Caucasian families and may contribute to linkage among non-northern European Caucasian families. This argues that P-5 may explain a portion, but not the majority of the linkage signal seen at D22S419. The UCSD/NIMH family set was separated into the indicated number of northern European Caucasian, non-northern European Caucasian and non-Caucasian families. For each group the number of transmissions (T) from heterozygotic parents to affected offspring determined by Transmit is listed. Since Transmit output lists the number of expected transmissions (E) rather than non-transmissions (N), N is calculated here from the relationship N=TÀ2(TÀE). For northern Europeans corresponding w 2 values determined by the 'robust' option and one-sided P values are indicated. Allele frequency in bipolars is the allele frequency of the variant in affected offspring of northern European Caucasians. Allele frequency on nontransmitting control chromosomes is estimated by dividing the allele frequency on transmitted chromosomes by the T: N ratio. Unambiguous haplotypes could be determined for all but one family. (+) indicates the haplotype has the variant base at that position. Clinical phenotypes in subjects with the P-5 variant Since variants conferring risk might be associated with specific clinical phenotypes, we examined the frequency of BP I vs BP II, anxiety diagnoses, and the presence of psychotic features during episodes of mania or depression among subjects inheriting P-5 and compared this to subjects without P-5 for the families of northern European Caucasian ancestry. A nonsignificant excess of BP II diagnoses was present in subjects with P-5. Among the 47 UCSD and 237 Toronto families were 17 subjects with P-5 of whom eight were BP I (47%) and nine were BP II (53%), whereas the subjects without P-5 were 66% BP I and 34% BP II. (Because the NIMH families were ascertained through BP I probands, they were not included in this analysis.) In the three family sets combined, a history of psychotic features was present in 11 of 17 P-5 positive BP I subjects (65%) compared with 60% among BP I subjects without P-5. The number of P-5 positive subjects with a secondary diagnosis of alcoholism or other drug dependence, panic disorder, panic attacks, or any anxiety diagnosis, was small and not clearly different from the frequency in subjects without P-5.
Discussion
We have screened the GRK3 gene for functional variants and identified six SNPs in the putative promoter region. We tested four of these SNPs for association with BPD. A statistically significant evidence was obtained indicating that the SNPdesignated P-5 is associated with disease in families of northern European ancestry. A trend toward support of this result was then obtained in an Table 3 . Table 3 .
Association of GRK3 with bipolar disorder TB Barrett et al independent sample. Among the 367 northern European Caucasian families in the combined sample, the allele frequency of SNP P-5 in affected offspring was 3% and an excess of transmission from heterozygotic parents to affected offspring was observed at a ratio of 26 transmissions to 7.7 non-transmissions, giving a w 2 of 9.6 and a P value for association of 0.0019. No evidence for association was found for SNPs 28 kb upstream or 114 and 150 kb downstream of exon 1, thereby providing some data to bracket the region of association. Together, these data argue for the association of BPD to the GRK3 gene.
These results must be qualified based on the statistical consideration that the overall estimate for the strength of the association in the combined data set should take into consideration a correction for multiple testing. Since the two promoter SNPs examined in the combined triad set are in strong LD and are found on shared haplotypes, the number of independent tests performed is less than two. Making an overly conservative Bonferroni correction for six tests (ie for two SNPs and for separation into three ethnic groups) gives a corrected P value of 0.011 which is still significant.
Further support for these results comes from a similar relative risk suggested by the two triad sets. Although the number of families in which P-5 is observed is small in both sets, the second set is a qualitatively similar replication of the first since the transmission-to-non-transmission ratio is approximately 3.4 in both triad sets.
The transmission-to-non-transmission ratio of 3.4 provides us with a first-order estimate for the relative risk conferred by the variant P-5. This is a relatively high-risk ratio for a polygenic complex disorder and suggests that a relatively strong biological effect is conferred by inheritance of the P-5 variant in individuals of northern European Caucasian ancestry. However, the overall population frequency of the P-5 variant is low; the observed allele frequency is 3% among offspring affected with BPD in these two family sets. Therefore, the P-5 variant conveys a moderate increase in risk, but in only a small portion of patients, and therefore likely has a relatively low population attributable risk. The combined set of 367 northern European Caucasian families (with 439 affected offspring) provides adequate power to detect association with disease as long as the marker is the disease variant or is in strong LD with the disease variant. For a marker with a population allele frequency of 1%, a heterozygotic genotype relative risk (Aa) of 3, a homozygotic genotype relative risk (AA) of 9, and an assumed disease frequency of 1%, this family set provides 93% power to detect association at a P value of 0.05. 29, 30 We chose to pursue a candidate gene approach based on the biological function, anatomical distribution, and chromosomal location of GRK3. We have judged that these considerations make it a more compelling candidate than other genes in the region. However, it is possible that either the linkage or LD results really reflect the functional effect of a mutation in another nearby gene. A 10 cM interval centered on the peak in evidence for linkage in the 22q12.1 region (that is, centered at the markers D22S925, 533, and 419, which, as discussed above, are located immediately centromeric to GRK3) spans just 4. 0 to the promoter provides some limited support that the observed association is indeed to the GRK3 gene.
If the P-5 variant is associated to BPD, then it could result from two possibilities. The P-5 variant might affect promoter function and be directly responsible for the susceptibility; alternatively, it may be close to and in linkage disequilibrium with the functional mutation which has yet to be identified. Several observations argue that the P-5 variant itself may not be the functional variant. One of these stems from the differences seen when stratifying by ethnicity. The necessity for separating the test families into major ethnic groups is justified by the long-standing observation that the prevalence for many disease mutations is highly distinct for different populations. Further, linkage disequilibrium relationships may vary between different populations. Although the numbers of non-Caucasian families in this study are very small, we see no trend toward excess transmission among non-Caucasians. Precedence is also well established for the prevalence of disease alleles varying markedly among subgroups of Caucasians. A large number of such examples have been extensively characterized in Ashkenazi Jews. While in our study the number of non-European Caucasians is too small to make definitive statements, there appears to be no trend toward excess transmission of any of the promoter SNPs tested. The simplest conclusion is that the variant is not itself a functional mutation, but in linkage disequilibrium with an adjacent functional variant. In this case, in northern European Caucasians, but not in non-northern Europeans, the P-5 variant would lie on a haplotype which carries a disease mutation outside of the region which we have sequenced. To investigate this possibility, we will need to determine the physical extent of linkage disequilibrium and of association with disease along these haplotypes, as well as to screen for mutations over a larger region. Alternatively, if the P-5 variant is the disease mutation, it is possible that an independently inherited epistatic risk co-factor operates together with P-5 to produce disease. Such a factor might be more prevalent in northern European Caucasians than in other populations. Conversely, a protective factor might be highly prevalent in nonnorthern Europeans.
Sequence analysis of the region containing the P-5 variant suggests some possible functions. The P-5 variant lies in the sequence GGGAGGG which has been shown to be a conserved DNA sequence motif in enhancer regions in a number of genes. 31, 32 Strikingly, when we compared the human to mouse genomic sequence of the upstream region of GRK3, we found not only that this GGGAGGG element is not present in mouse, but also that the P-5 variant is located in a short DNA stretch which is unique to human sequence (see Figure 3) . The P-6 variant is a single G deletion out of a run of 8 G's lying at the base of a potential hairpin structure formed by 12 G-C pairs. Such hairpin structures in UTRs have been shown to have significant regulatory effects on translation. 33 However, as is true for P-5, this hairpin and the P-6 variant do not have homology in the murine genomic sequence. Interestingly then, both these variants might pertain to functions of GRK3 that are unique to only certain mammals or to primates. Likewise, the other promoter variants we have identified lie in sequence for which there is only moderate-to-minimal similarity between human and mouse, and only one variant, P-2, is the identical nucleotide in both species.
In summary, we have identified variants in GRK3 which may affect the regulation of gene expression, and have shown that they are associated with increased susceptibility for disease. These data suggest the hypothesis that a dysregulation in the time or place of GRK3 expression results in aberrant neurotransmitter signaling and an increased susceptibility to develop BPD. The narrowest formulation of this hypothesis is that a failure of dopamine receptor homologous desensitization results in an effective hypersensitivity to dopamine and can cause a susceptibility to disease. A broader formulation takes into account the fact that GRK3 has been demonstrated to desensitize many GPCRs, including adrenergic, muscarinic, histaminic, dopaminergic, CRF-1, and opioid receptors. [12] [13] [14] [15] [16] 21 GRK3 might, therefore, play an important role in the regulation of any one of many GPCRs, and the regulation might be either presynaptic or postsynaptic and might involve either stimulatory or inhibitory circuits. The complexity of these functions raises the possibility that different mutations each responsible for distinct changes in the time and place of GRK3 expression could have strikingly different effects on GPCR regulation and thus be associated with distinct subphenotypes of BPD.
A final possibility is that variants in the time or place of GRK3 expression might result in a more complicated perturbation (dysregulation) of signaling than a mere failure in homologous desensitization. Following phosphorylation by GRKs, b-adrenergic receptors are bound by b-Arrestin which terminates G protein-induced signaling and initiates clatherinmediated endocytosis.
14,15 b-arrestin has been shown capable of initiating subsequent intracellular signaling through MAP kinase pathways. 34 Therefore, changed expression of GRK3 in specific neurons could have complicated effects on multiple aspects of neurotransmitter signaling. Together, the multiple intriguing roles of GRK3 in neuronal signaling in conjunction with the data for association that we here report argue for the role of GRK3 in the susceptibility to BPD.
